Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

INSIDE INFORMATION

NEW DRUG APPLICATION OF OUR CORE PRODUCT OT-401 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Ocumension Therapeutics (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors of the Company is pleased to announce that the new drug application ("**NDA**") for OT-401 (YUTIQ, product name: Youshiying (優施瑩)), the core product of the Company, has been approved by the Center for Drug Evaluation of the National Medical Products Administration (the "**NMPA**") of the People's Republic of China (the "**PRC**" or "**China**") for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye ("**chronic NIU-PS**") and commercialization in the PRC. The research data showed that OT-401 could significantly reduce the recurrence rate and disease burden for patients with chronic non-infectious uveitis, improve visual acuity and the safety profile is favorable. It is believed that the approval for marketing of OT-401 will bring hope to patients with chronic NIU-PS in China.

Information on OT-401

OT-401 (YUTIQ) is a first-in-class, innovative injectable, sustained-release micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye in-licensed from EyePoint Pharmaceuticals, Inc. OT-401 is a sterile non-bioerodible intravitreal implant designed to provide sustained release of a total of 0.18mg of the active ingredient fluocinolone acetonide, a corticosteroid, at a controlled rate for up to 36 months from a single administration performed in an outpatient visit. To date, YUTIQ is the first and only uveitis treatment designed to deliver fluocinolone for up to 36 months that has been approved by the United States Food and Drug Administration (FDA).

Information on Chronic NIU-PS

The typical characteristics of uveitis are the early stage of onset and recurrence. The average age of onset is around 33 years old. Each episode of inflammation would cause irreversible damage to the patient's intraocular tissues. As a result, 46% of patients will eventually develop irreversible low vision or blindness. It is the second most common blind eye disease in China to which there is currently no standard treatment in the country.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The Company cannot guarantee that OT-401 will ultimately be successfully marketed.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, June 21, 2022

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.